Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.



Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults.

Authors: Bruce D, Burnham S, Dore V, Fraser PE, Gaskin S, Laws SM, Li QX, Martins RN, Maruff P, Masters CL, Newsholme P, Porter T, Rainey-Smith S, Rowe CC, Salvado O, Srikanth V, Verdile G, Villemagne VL, Wijesekara N, Woodfield A

Journal: Scientific Reports

Volume & Issue: 7 & 1

Page No.: 9766

DOI: 10.1038/s41598-017-09577-4

Year Published: 2017

Growing evidence supports the hypothesis that type 2 diabetes (T2D) increases the risk of developing dementia. Experimental evidence from mouse models demonstrates that the induction of T2D/insulin resistance (IR) can promote the accumulation of Alzheimer’s disease (AD) pathological features. However, the association of T2D with pathological and clinical phenotypes in humans is unclear. Here we […]

Vascular burden and Alzheimer disease pathologic progression.

Authors: Jagust WJ, Lo RY

Journal: Neurology

Volume & Issue: 79 & 13

Page No.: 1349-55

Year Published: 2012

OBJECTIVE: To investigate the vascular contribution to longitudinal changes in Alzheimer disease (AD) biomarkers. METHODS: The Alzheimer’s Disease Neuroimaging Initiative is a clinic based, longitudinal study with CSF, PET, and MRI biomarkers repeatedly measured in participants with normal cognition (NC), mild cognitive impairment (MCI), and mild AD. Participants with severe cerebrovascular risks were excluded. Cardiovascular […]

Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment.

Authors: Barnes J, Bartlett JW, Fox NC, Leung KK, Ourselin S, Schott JM

Journal: Neurobiology of Aging

Volume & Issue: 31 & 8

Page No.: 1452-62

DOI: 10.1016/j.neurobiolaging.2010.04.011

Year Published: 2010

Cerebral atrophy rate is increasingly used as an outcome measure for Alzheimer’s disease (AD) trials. We used the Alzheimer’s disease Neuroimaging initiative (ADNI) dataset to assess if adjusting for baseline characteristics can reduce sample sizes. Controls (n = 199), patients with mild cognitive impairment (MCI) (n = 334) and AD (n = 144) had two […]